Zhitong Finance App News, Zhongsheng Pharmaceutical (002317.SZ) issued an announcement. Recently, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (“Zhongsheng Ruichuang”), the company's holding subsidiary, received a patent certificate issued by the Japan Patent Office (Japan Patent Office). Patent involved: “Preparation and application of polypeptides”. This patent is a compound patent for the company's RAY1225 project and is the core patent of this project. RAY1225 injection is a polypeptide drug with dual agonistic activity of GLP-1 receptors and GIP receptors. Thanks to its excellent pharmacokinetic properties, it has the potential to be injected every two weeks as a long-term drug. Currently, RAY1225 injection is in phase III clinical trials. Subsequent companies will proceed with the research and development of the project in an orderly manner according to the plan.

Zhitong Finance App News, Zhongsheng Pharmaceutical (002317.SZ) issued an announcement. Recently, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (“Zhongsheng Ruichuang”), the company's holding subsidiary, received a patent certificate issued by the Japan Patent Office (Japan Patent Office). Patent involved: “Preparation and application of polypeptides”. This patent is a compound patent for the company's RAY1225 project and is the core patent of this project. RAY1225 injection is a polypeptide drug with dual agonistic activity of GLP-1 receptors and GIP receptors. Thanks to its excellent pharmacokinetic properties, it has the potential to be injected every two weeks as a long-term drug. Currently, RAY1225 injection is in phase III clinical trials. Subsequent companies will proceed with the research and development of the project in an orderly manner according to the plan.